Summary

Eligibility
for people ages 18-80 (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
completion around

Description

Summary

People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth. This type of pill is called "Bruton Tyrosine Kinase Inhibitor" or BTKi. Another treatment for CLL/SLL is a different pill called venetoclax.

The purpose of this study is to compare continuing the current treatment with BTKi alone, as long as it is working, to another arm of treatment which adds venetoclax to the current treatment (BTKi), for one year. After one year, both pills in this arm of treatment would be stopped and the participants will be closely monitored.

Official Title

Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Details

Keywords

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Leukemia, Lymphoma, Lymphoid Leukemia, Leukemia, Lymphocytic, Chronic, B-Cell, Venetoclax, Zanubrutinib, Acalabrutinib, Ibrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib, Continue BTKi single agent, BTKi + Venetoclax for 12 cycles, then discontinue

Eligibility

Locations

  • San Francisco VA Medical Center, San Francisco, CA
    San Francisco California 94121-1563 United States
  • VA Puget Sound Health Care System Seattle Division, Seattle, WA
    Seattle Washington 98108-1532 United States
  • Kansas City VA Medical Center, Kansas City, MO
    Kansas City Missouri 64128-2226 United States
  • Durham VA Medical Center, Durham, NC
    Durham North Carolina 27705-3875 United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
VA Office of Research and Development
ID
NCT06520098
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 100 study participants
Last Updated